Sen. Laura Ellman supports SB3049 to broaden and rename newborn screening panel

Sen. Laura Ellman (D-21st) cast a Yes vote for SB3049, which renames and broadens the scope of the newborn screening advisory committee, during the 104th General Assembly on May 31, 2026, according to the Illinois Senate. The bill passed unanimously in the Senate with a 54-0 vote.

The official bill text describes the proposal as: "NEWBORN METABOLIC SCREENING."

The section below provides an explanation based on the bill’s text, which may interpret and clarify its contents.

The legislation changes the name of the Genetic and Metabolic Diseases Advisory Committee to the Universal Newborn Screening Advisory Committee and increases its responsibilities in advising the state’s newborn screening program. Beginning July 1, 2026, the committee is required to hold quarterly meetings, systematically review conditions based on federal and treatment-based criteria, and specifically assess several rare disorders—including certain mucopolysaccharidoses and Batten disease type 2—for consideration to be added to the newborn screening panel. The law outlines deadlines for reviews, implementation actions by state labs, public annual reporting, and updates references in related statutes such as the Rare Disease Commission Act. The bill becomes effective immediately.

The official action recorded for SB3049 was 'House Committee Amendment No. 1 Senate Concurs'.

Ellman earned her BS from Grinnell College in 1987.

Ellman, a Democrat, joined the Illinois State Senate in 2019 representing the 21st Senate District, succeeding Michael Connelly.

Illinois legislation advances through a multi-stage legislative process with initial introduction, committee consideration, floor debate, and votes in both chambers before being sent to the governor for signature or veto. The General Assembly works on a two-year cycle. Each session, thousands of bills are introduced, though only a select number complete the process to become law.